Ascend Research

SRAD earnings

Analysis, not advice
Next print
2026-08-04
cons 0.06 EPS / 0.44B rev
The desk's graded verdict
intactgraded 2026-05-24
PASSFY26 full-year guidance reaffirmed

we reaffirming of our '26 full year financial outlook. This reflects the great confidence we have in our business model

PASSNo partner terminations or contract renegotiations reported

we reject the unfounded and misinformed allegations... we continue to conduct our business in a manner consistent with the highest standards

6 more resolved criteria + the full narrative on the deskfree trial · no card

Educational analysis, not a personalised recommendation. See all covered names on the earnings calendar · part of our public track record.